Loading
A phase 3 trial of PSMA-1007 F-18 run by ABX advanced biochemical compounds GmbH in prostate cancer, now recruiting.
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer is a phase 3 interventional study registered as NCT06122584 by ABX advanced biochemical compounds GmbH, with 380 participants planned, started 2024-06-13. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.